Erlonat (Erlotinib) Tablets is used for the treatment of patients with Non-small cell lung cancer and Pancreatic cancer

Erlonat is a kinase inhibitor indicated for: • Maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. • Treatment of locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. • First-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine.

Erlonat (Erlotinib) Tablets suppliers in India. Indian Pharma Network (IPN) New Delhi, INDIA.

IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.

For procurement cost of Erlonat (Erlotinib) Tablets brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the Erlonat (Erlotinib) Tablets tablets cost price in India.

The order for Erlonat (Erlotinib) Tablets will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

Erlotinib is a cancer medicine that interferes with the growth of cancer cells and slows their spread in the body. Erlotinib is used to treat non-small cell lung cancer or pancreatic cancer that has spread to other parts of the body (metastatic)

Erlonat (Erlotinib) Tablets, for oral use.

Generic Name: Erlotinib

Erlonat (Erlotinib) Tablets

Erlonat (Erlotinib) Tablets tablets, for oral use is available.

Get In Touch

Indian Pharma Network (IPN), Delhi. India

IPN, Delhi is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India. IPN, New Delhi helps patient, providing solutions on how to get access of anti cancer medicines which is not available in India.

BRANCH OFFICE : NEW DELHI | BENGALURU | KOLKATA | LUCKNOW | JODHPUR

Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Saudi Arabia | South Africa

Indian Pharma Network

60/4 1st Floor, T&T Building, Indian Oil Complex,
Yusuf Sarai, New Delhi, Delhi 110016

Mobile / WhatsApp / Phone

M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398

Free Customer Support

info@indianpharmanetwork.co.in
urgent@indianpharmanetwork.co.in

Erlonat (Erlotinib) Tablets suppliers in India

IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand Erlonat (Erlotinib) Tablets on prescription and Import License in Patient's Name only.

For overseas patients, Erlonat (Erlotinib) Tablets can be made available in Send your enquiry to find Erlonat (Erlotinib) Tablets in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.

News / Update for Erlonat (Erlotinib) Tablets injection.

For Erlonat (Erlotinib) Tablets Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details

AstraZeneca and Merck's Lynparza cleared by FDA for pancreatic cancer For More Details

Ramucirumab Plus Erlotinib Shows PFS Benefit in Frontline EGFR+ NSCLC